Diabetes Research Centers (P30 Clinical Trial Optional)
ID: 359145Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359145
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Diabetes Research Centers (P30 Clinical Trial Optional) grant, aimed at enhancing national research efforts in diabetes and related diseases. This funding opportunity encourages collaboration among basic and clinical investigators by providing shared technical resources and a Pilot and Feasibility Program, with a focus on innovative approaches and synergies with other NIDDK-funded programs. Eligible applicants include various higher education institutions, nonprofits, and government entities, with a maximum funding amount of $1 million per year, and a total estimated program funding of $18.2 million for approximately seven awards. Interested parties should note that the application deadline is January 27, 2027, and can reach out to the Division of Diabetes, Endocrinology and Metabolic Diseases at NIDDK_DEM@nih.gov for further information.

    Point(s) of Contact
    NIDDK_DEM@nih.gov
    Files
    Title
    Posted
    RFA-DK-26-310-Full-Announcement.html
    The Department of Health and Human Services is reissuing RFA-DK-26-310 for Diabetes Research Centers (DRCs), inviting applications to support and enhance national research efforts in diabetes, its complications, and related endocrine and metabolic diseases. The program aims to foster collaboration among basic and clinical investigators by providing shared technical resources (research cores) and a Pilot and Feasibility Program. DRCs must include an Administrative Core, at least two Biomedical Research Cores, and a Pilot and Feasibility Grant Program. The funding opportunity encourages new approaches, unique scientific themes, and innovative resources, emphasizing synergies with other NIDDK-funded programs and mentoring for future researchers. The annual direct cost budget is limited to $1,000,000, or $1,250,000 for those proposing a Regional/National Shared Research Core or expanded P&F Program. Eligible applicants include various higher education institutions, nonprofits, and government entities, with a maximum project period of five years. Only one application per institution is allowed.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Diabetes Research Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for Diabetes Research Centers (P30 Clinical Trial Optional), aimed at enhancing research collaboration and innovation in diabetes and related metabolic disorders. This initiative seeks to establish a community of preclinical and clinical researchers, providing access to specialized resources and a Pilot and Feasibility Program to foster significant advancements beyond individual project capabilities. With an estimated total program funding of $18.2 million and an award ceiling of $1 million, the NIH anticipates making approximately seven awards, encouraging applications from a diverse range of eligible entities, including non-domestic institutions and community-based organizations. Interested parties should prepare for the application process, as the estimated synopsis post date is July 30, 2025, with applications expected to be solicited by March 11, 2026, and awards anticipated by December 30, 2026. For further inquiries, contact Dr. Christopher J. Lynch at lynchcj@nih.gov or call 301-325-4232.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering Research Education Program Grants (R25) to enhance training in biomedical, behavioral, and clinical research. This funding opportunity aims to support educational activities that develop research skills and provide hands-on experiences in areas critical to NIDDK, including diabetes, digestive diseases, and obesity. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and local governments, with a funding limit of $100,000 per year for up to five years. The application deadline is January 30, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-074.html.
    Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for collaborative research projects focused on type 1 diabetes, specifically utilizing biosamples and data from established clinical studies. The objective is to advance the understanding of the disease's etiology and pathogenesis, with funding available for studies that aim to explore disease mechanisms, delay onset, and improve prevention strategies. A total of $5.5 million is committed for up to four awards in Fiscal Years 2026 and 2027, with application deadlines beginning on May 26, 2025, and a final submission date of March 9, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated, high-risk multi-center clinical trials through the Notice of Funding Opportunity (NOFO) PA-25-147. This cooperative agreement (U01) aims to support innovative studies that address critical health issues related to diabetes, digestive diseases, and kidney conditions, requiring proposals to be hypothesis-driven and operationally classified as high-risk. The program emphasizes the importance of diverse perspectives in research and mandates that planning activities be completed prior to application submission. Interested applicants should note that the application period opens on January 3, 2025, with a submission deadline of November 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk, multi-center observational studies related to diabetes, digestive, kidney, and associated diseases. This funding opportunity emphasizes hypothesis-driven research that engages diverse populations, particularly underserved communities, and requires a comprehensive study design, community engagement, and a detailed budget. The initiative is crucial for advancing health equity and enhancing participant diversity in clinical research. Interested applicants should note that the submission period opens on January 3, 2025, with a closing date of November 5, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)." This initiative aims to support high-risk, investigator-initiated, multi-center clinical studies by facilitating early peer review and the development of essential operational documents necessary for conducting the proposed studies. The program emphasizes the importance of addressing diseases affecting underrepresented populations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) in their submissions. The maximum award amount is $225,000 per year for up to two years, with applications opening on May 9, 2025, and a submission deadline of June 10, 2027. Interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trial Required)." This initiative aims to explore the efficacy and clinical effectiveness of multimodality digital health technology approaches, such as continuous glucose monitoring and telemedicine, in the remote management of diabetes. The research is crucial for enhancing the understanding of diabetes management, prevention, diagnosis, and treatment, with a focus on improving health outcomes. The NIH anticipates awarding three grants for projects lasting up to five years, with application deadlines set for November 7, 2025, and October 6, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-26-315.html.